氨溴索联合莫西沙星对老年重症社区获得性肺炎患者的疗效及外周血T淋巴细胞亚群的影响
|
摘要
目的探讨氨溴索联合莫西沙星对老年重症社区获得性肺炎患者的疗效及外周血T淋巴细胞亚群的影响。方法选取2015年5月—2017年12月入院治疗老年重症社区获得性肺炎的90例患者作为研究对象,随机分为观察组与对照组两组,每组各45例。观察组给予氨溴索联合莫西沙星治疗,对照组仅给予莫西沙星治疗,持续治疗10天后,观察两组患者的治疗效果及临床指标。结果两组患者的总有效率分别为95.56%和82.22%(P<0.05)。治疗后观察组患者症状消失的时间均短于对照组(P<0.05)。观察组患者的T淋巴细胞亚群比例高于对照组(P<0.05)。结论氨溴索联合莫西沙星治疗老年重症社区获得性肺炎患者,提高了患者治疗的有效率,明显改善了患者的症状,提高患者的免疫力。
Objective To explore the efficacy of ambroxol combined with moxifloxacin on elderly patients with severe community acquired pneumonia and its influence on peripheral blood T lymphocyte subsets. Methods 90 cases of elderly patients,those who suffered with severe community acquired pneumonia and admitted in our hospital during May 2015 and December 2017,were enrolled in this study and randomly divided into the observation group and the control group,45 cases in each group. The observation group was treated with ambroxol combined with moxifloxacin. The control group was treated with moxifloxacin only. The treatment effect and clinical indexes of the two groups were observed after 10 days of continuous treatment. Results The total effective rates of the two groups were 95.56% and 82.22% respectively( P< 0.05). After treatment,the time of symptom disappearance in the observation group was shorter than that in the control group( P<0.05). The proportion of T lymphocyte subsets in the observation group was higher than that in the control group( P<0.05).Conclusions Ambroxol combined with moxifloxacin in the treatment of elderly patients with severe community acquired pneumonia can improve the efficiency of the treatment,improve the symptoms of the patients and improve the immunity of the patients.
Objective To explore the efficacy of ambroxol combined with moxifloxacin on elderly patients with severe community acquired pneumonia and its influence on peripheral blood T lymphocyte subsets. Methods 90 cases of elderly patients,those who suffered with severe community acquired pneumonia and admitted in our hospital during May 2015 and December 2017,were enrolled in this study and randomly divided into the observation group and the control group,45 cases in each group. The observation group was treated with ambroxol combined with moxifloxacin. The control group was treated with moxifloxacin only. The treatment effect and clinical indexes of the two groups were observed after 10 days of continuous treatment. Results The total effective rates of the two groups were 95.56% and 82.22% respectively( P< 0.05). After treatment,the time of symptom disappearance in the observation group was shorter than that in the control group( P<0.05). The proportion of T lymphocyte subsets in the observation group was higher than that in the control group( P<0.05).Conclusions Ambroxol combined with moxifloxacin in the treatment of elderly patients with severe community acquired pneumonia can improve the efficiency of the treatment,improve the symptoms of the patients and improve the immunity of the patients.
引文
[1]中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655.
[2]田祺,魏媛,封继宏.老年性肺炎中医药诊疗研究进展[J].光明中医,2017,32(19):2887-2889.
[3]王敏,马爱矿,王晓蓉.老年社区获得性肺炎人群临床特点、危险因素以及病原菌的耐药性分析[J].中国卫生检验杂志,2017,27(24):3639-3641.
[4]李淑芬.莫西沙星治疗老年社区获得性肺炎的临床研究[J].中国医药指南,2016,14(19):129-130.
[5]杜家杰.十味龙胆花颗粒联合头孢曲松钠治疗老年社区获得性肺炎的临床研究[J].现代药物与临床,2018,33(4):813-816.
[6]范建,范贤明.老年肺炎的研究进展[J].中国老年学杂志,2016,36(15):3859-3861.
[7]徐艳秋.化痰逐瘀汤治疗老年社区获得性肺炎临床观察[J].光明中医,2018(9):1267-1268.
[8]刘武胜,李如梅,宋志锋,等.国内莫西沙星治疗老年社区获得性肺炎的临床疗效的meta分析[J].当代医学,2017,23(9):8-10.
[9]王曦东.盐酸氨溴索注射液不同剂量辅助治疗老年肺炎的疗效分析[J].基层医学论坛,2017,21(13):1614-1616.
[10]孟新升.盐酸氨溴索联合莫西沙星治疗肺炎的疗效及安全性分析[J].健康之路,2017,16(5):64.
[11]陈占峰,万春辉.蒲地兰联合阿奇霉素对小儿支原体肺炎患者T淋巴细胞亚群临床影响研究[J].河北医学,2016,22(10):1647-1649.
[12]Beeh KM,Beier J,Esperester A,et a1.Antiinflammatory properties of ambroxol[J].Eur J Med Res,2008,13(12):557-562.
[13]Cataldi M,Sblendorio V,Leo A,et a1.Biofilm-dependent airway infections:a role for ambroxol[J].Pulm Pharmacol Ther,2014,28(2):98-108.
[2]田祺,魏媛,封继宏.老年性肺炎中医药诊疗研究进展[J].光明中医,2017,32(19):2887-2889.
[3]王敏,马爱矿,王晓蓉.老年社区获得性肺炎人群临床特点、危险因素以及病原菌的耐药性分析[J].中国卫生检验杂志,2017,27(24):3639-3641.
[4]李淑芬.莫西沙星治疗老年社区获得性肺炎的临床研究[J].中国医药指南,2016,14(19):129-130.
[5]杜家杰.十味龙胆花颗粒联合头孢曲松钠治疗老年社区获得性肺炎的临床研究[J].现代药物与临床,2018,33(4):813-816.
[6]范建,范贤明.老年肺炎的研究进展[J].中国老年学杂志,2016,36(15):3859-3861.
[7]徐艳秋.化痰逐瘀汤治疗老年社区获得性肺炎临床观察[J].光明中医,2018(9):1267-1268.
[8]刘武胜,李如梅,宋志锋,等.国内莫西沙星治疗老年社区获得性肺炎的临床疗效的meta分析[J].当代医学,2017,23(9):8-10.
[9]王曦东.盐酸氨溴索注射液不同剂量辅助治疗老年肺炎的疗效分析[J].基层医学论坛,2017,21(13):1614-1616.
[10]孟新升.盐酸氨溴索联合莫西沙星治疗肺炎的疗效及安全性分析[J].健康之路,2017,16(5):64.
[11]陈占峰,万春辉.蒲地兰联合阿奇霉素对小儿支原体肺炎患者T淋巴细胞亚群临床影响研究[J].河北医学,2016,22(10):1647-1649.
[12]Beeh KM,Beier J,Esperester A,et a1.Antiinflammatory properties of ambroxol[J].Eur J Med Res,2008,13(12):557-562.
[13]Cataldi M,Sblendorio V,Leo A,et a1.Biofilm-dependent airway infections:a role for ambroxol[J].Pulm Pharmacol Ther,2014,28(2):98-108.